GM says physical silver is important
https://youtu.be/iVXExabOCGM
#crypto #trading #banned
MARKETS A LOOK AHEAD: Critical MUST KNOW NOW Updates. Mannarino
27,954 views
Oct 17, 2021
Bryson Gray
178K subscribers
I'M LIVE: QUICK LATE NIGHT STREAM
I'M LIVE: QUICK LATE NIGHT STREAM
221 watching now
Started streaming 22 minutes ago
https://gab.com/SarahLowrey/posts/107118323143021611
Remdesivir, the only approved treatment for hospitalized patients, cost an estimated $5 (pdf) to produce and was sold to the U.S. government for $2,340 a course—a price now pegged too high for many patients. Monoclonal antibody courses, used to treat mild or asymptomatic COVID-19 cases, cost around $2,100 per course. The cost of production for the monoclonals is not clear.
https://www.theepochtimes.com/mkt_breakingnews/us-set-to-pay-712-per-patient-for-mercks-covid-19-pill_4050864.html
https://gab.com/AmericaTruther/posts/107114652123448195
Cyndexia
Cyndexia
@AmericaTruther
1d
·
·
Trump 2020
👇 Heartbreaking … Thank you Sir for Your Service 🇺🇸
“This is the last time you’ll hear me in a patrol car and Jay Inslee can kiss my ass.”
Washington State Trooper in Yakima, Wash. signs off after 22 years — fired by Gov Inslee for being unvaccinated.
https://gab.com/Shepherd/posts/107118469683165088
https://www.theepochtimes.com/mkt_breakingnews/us-set-to-pay-712-per-patient-for-mercks-covid-19-pill_4050864.html
Cheaper Than Other Treatments
While hydroxychloroquine and other drugs approved for various afflictions but used as off-label COVID-19 treatments cost much less, they aren’t recommended by federal authorities to treat COVID-19. The few cleared as COVID-19 treatments cost more than Merck’s drug.
Remdesivir, the only approved treatment for hospitalized patients, costs an estimated $5 (pdf) to produce and was sold to the U.S. government for $2,340 a course—a price now pegged as too high for many patients. Monoclonal antibody courses, used to treat mild or asymptomatic COVID-19 cases, cost around $2,100 per course. The cost of production for the monoclonals isn’t clear.
Merck’s drug “is lower than a lot of the other treatments right now for COVID” and “certainly a lot cheaper in the United States of ending up in a hospital,” James Love, director of Knowledge Ecology International, told The Epoch Times.
“On the face of it, that doesn’t seem to be, initially, an irresponsible pricing decision for Merck,” he said.
The average COVID-19 hospitalization costs $34,662 to $45,683, according to data crunched by FAIR Health (pdf).
If regulators do find the drug safe—there are concerns it could lead to the development of cancer—and authorize it in the United States, the calculus could change.
“Suppose that a new variant ended up infecting a significant percentage of the U.S. population and the drug was needed for 1 million, 10 million, or 50 million persons. At some point, the price just isn’t reasonable,” Love said in an email.
Dr. Roger Klein, a health policy expert who currently advises The Heartland Institute, doesn’t see the gap as a big deal, given that developing treatments are “really high-risk endeavors” that cost a lot of money, including millions of dollars just to run clinical trials.
“We don’t know how long these drugs are going to have a market within the United States, which is the world’s most important drug market in many ways,” he told The Epoch Times, adding that he believes the public health crisis from the pandemic is close to being over because of an increasing number of people gaining immunity through vaccination or prior infection.
Every treatment costs much more than vaccines. The shots have all been priced under $20 a dose, according to contracts between vaccine makers and the U.S. government.